Keyphrases
Actinic Keratosis
100%
Adult Patients
20%
Clinical Efficacy
20%
Denmark
40%
Diclofenac
40%
EQ-5D-5L
20%
EQ-VAS
20%
Field Treatment
100%
Health-related Quality of Life
60%
Improved Health
20%
Ingenol Mebutate
60%
Instrument Validation
20%
Non-adherence
20%
Non-persistence
20%
Patient Health Questionnaire
20%
Patient-reported Outcomes
100%
Physician Questionnaire
20%
Randomized Clinical Trial
20%
Real-world Clinical Practice
20%
Routine Clinical Practice
40%
Satisfaction with Treatment
20%
Short-term Treatment
20%
Sweden
40%
Topical Treatment
40%
Treatment Adherence
100%
Treatment Duration
20%
Treatment Efficacy
20%
Treatment Satisfaction
60%
Medicine and Dentistry
Actinic Keratosis
100%
Combination Therapy
25%
Dermatology
25%
Diclofenac
75%
Ingenol Mebutate
75%
Patient Compliance
100%
Patient-Reported Outcome
100%
Quality of Life
75%
Randomized Clinical Trial
25%
Topical Treatment
50%
Treatment Duration
25%
Nursing and Health Professions
Actinic Keratosis
100%
Clinical Practice
75%
Combination Therapy
25%
Diclofenac
75%
Patient Compliance
100%
Patient-Reported Outcome
100%
Quality of Life
75%
Topical Treatment
50%
Treatment Duration
25%
Pharmacology, Toxicology and Pharmaceutical Science
Actinic Keratosis
100%
Combination Therapy
33%
Diclofenac
100%
Imiquimod
66%
Ingenol Mebutate
100%
Randomized Clinical Trial
33%